Most Recent
Danish company Vestesen Hybrid Energy has taken Zenith Energy to court for allegedly infringing its patented system for operating an electrical grid where energy is generated by a fluctuating renewable energy source.
Zoetis has been ordered to pay Scidera’s costs of defending an unsuccessful summary dismissal application on a lump sum basis in a dispute over a bovine gene patent, with a judge rejecting its “premature” bid for a set-off.
Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea.
A judge has declined to order US-based animal genomics company Scidera to file a position statement in its bovine gene patent infringement suit and said she was “running out of patience” after unsuccessful strike-out and summary dismissal applications by the defendants.
Isuzu has lost an appeal bid to shut down a lawsuit by car alarm company Directed Electronics over alleged trade secrets theft, after an earlier case left it with a $169 million damages bill.
Animal drug company Zoetis has lost its bid for summary dismissal of claims that it infringed US-based animal genomics company Scidera's bovine gene patent, with a judge saying its novel arguments were not so clear-cut and needed to be worked out at trial.
The owner of luxury brand Van Cleef & Arpels has taken retailers Target and Kmart to court, alleging they infringed its trade marks and violated consumer law by selling jewellery that copy its hallmark clover and flower motifs worn by countless celebrities and royalty.
Biotech Regeneron and drug company Bayer have wasted no time in challenging a decision that cleared the way for generic pharmaceutical manufacturer Sandoz to launch a version of top selling Eylea.
Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.
The High Court has rejected Novartis' plea that it overturn a ruling that found an extension of the term of the patent for its heart drug Entresto was invalidly granted.